AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Geratherm Medical AG

Interim / Quarterly Report Aug 23, 2006

178_10-q_2006-08-23_6d1a1b2b-b01c-4b4d-a019-e41c251ea356.pdf

Interim / Quarterly Report

Open in Viewer

Opens in native device viewer

Course of Business from 1 January to 30 June 2006

  • Turnover first half of 2006 + 4.3% Q II +3.2%
  • EPS first half of 2006 8 cents Q II 3 cents
  • Dollar exchange rate burdens operating result in 2nd quarter

Dear shareholders of and parties interested in Geratherm Medical,

The business development during the 2nd quarter of 2006 resulted in a turnover plus of 3.2% and thus met our expectations, to a great degree. All in all, the turnover during the first six months of the business year amounted to EUR 4.2 million (+4.3%). The crude result from this turnover increased during the first half of 2006 by 3.0% respectively to reach EUR 2.3 million. The growth in turnover came especially from the new markets of Brazil and the Middle East. The business in Germany was somewhat weaker with a minus of 12.2%. The sales throughout Europe, recording a minus of 2.3%, were slightly below the previous year's level. The drop in turnover in the US market during the 1st quarter of 2006 could be evened out by a stronger 2nd quarter – as planned – and was in line with the previous year's level as per 30 June 2006.

The operating result of the 1st half of 2006 amounted to 24.9% less than last year's level, due to the start-up losses of our subsidiary apoplex medical technologies GmbH and exchange rate differences relating to a weaker dollar on the accounting date. During the 2nd quarter of 2006, an operating result of only kEUR 23 could be achieved. Losses from exchange rate differences in the amount of kEUR 63 (previous year: earnings from exchange rate differences kEUR 55) had a negative impact on the balance. These resulted mainly from the evaluation of short-term assets, such as receivables and cash in US dollars, at the accounting date exchange rate of EUR/USD 1.27 (previous year.: EUR/USD 1.21). By increase in inventories of kEUR 81, the operating result was burdened with kEUR 30 in the 2nd quarter. The apoplex GmbH company recorded a loss of kEUR 46 during the 2nd quarter.

A positive financial result could be achieved for the first half of 2006 in the amount of kEUR 138 (previous year: kEUR 194). Due to the positive development of the securities holdings, there were Market Evaluation Provisions of kEUR 630 relating to non-realised financial returns, which are not included in the profit and loss accounts but rather in the equity capital. The result of ordinary business activities was reduced by altogether 26.5% to reach kEUR 366 (previous year: kEUR 497). The Group Period Result (EAT) was reduced by 27.5% to reach kEUR 358 (previous year: kEUR 494). The result per share was reduced to 8 cents (previous year: 11 cents).

The equity capital of the company of EUR 16.5 million amounts to 92.2% of the balance sheet total or EUR 3.66 per share. The return on equity amounts to 4.3 % (previous year: 6.1%). As per 30 June 2006, cash and securities were included in the amount of EUR 8.4 million (previous year: EUR 8.0 million). The cash in the amount of EUR 3.3 million is invested with banks at the interest rates usual in the market.

Once again, the analogue diagnostics products on the basis of gallium proved the mainstays of turnover with 43.7% (previous year: 48.4%). The absolute turnover share was slightly reduced by kEUR 116 to reach kEUR 1,840 in the first half of 2006. The area of Digital Diagnostics was able to latch on to the previous growth and recorded a turnover plus of 11.8% during the first half of the year.

Turnover by segments 01.01.-30.06.2006

The turnover share of the Other Products area increased over proportionately during the first half of the year and recorded a plus of 19.6%. This growth was achieved, above all, through the positive turnover development in the area of Warming Systems. For the second half of 2006, we anticipate a further distinct increase of this area, especially, as we are expecting the award of a large order of 120 systems for Indian military hospitals in the 3rd quarter.

The subsidiary apoplex medical technologies GmbH was not able to contribute any turnover worth mentioning in the first half of 2006. Staff of sales partners is being trained at the moment, so that we will gain an overview of the market acceptance of the products over the next few months.

Turnover by regions 01.01.-30.06.2006

A share of 81% of the EUR 4.2 million turnover achieved during the first half of 2006 came from exports. The weaker domestic demand could be more than compensated through stronger foreign business, just as in the first quarter of 2006. The distribution of the turnover across the individual regions remained more or less unchanged. The strongest growth in turnover was achieved by the Region of the Middle East with a plus of 40% and Brazil with a plus of 204%. All in all, these countries achieved a turnover of kEUR 620.

II/06 I/06 IV/05 III/05 II/05
Data and facts Turnover 2,031 2,182 2,062 2,088 1,968
(kEUR) EBITDA 5.4% 12.8 % 6.6 % 17.3 % 15.1 %
EBIT 23 205 46 268 205
EPS (EUR) 0.03 0.05 0.07 0.15 0.08
Cashflow 88 262 158 338 273

All, items of the agenda were discussed and approved of by our shareholders at the ordinary shareholders' meeting in Frankfurt am Main on 12 June 2006.

Geratherm Medical AG has paid out to its shareholders a tax-free dividend in the amount of 32 cents per share for the business year of 2005 from the deposit account.

We anticipate a positive development for the second half of 2006, although we expect a weaker turnover for the 3rd quarter of 2006. The financial returns should reach a distinctly higher level through the realisation of the book profits. The approvals in the area of warming systems for the US military are running according to plan.

Geschwenda, dated August 2006

Dr. Gert Frank Thomas Robst

Chairman of the Board Director of Sales & Marketing

GERATHERM AT A GLANCE

Group financial ratio Jan.-June 2006 Jan.-June 2005 Change
Sales 4,213 kEUR 4,041 kEUR 4.3 %
Export share 3,401 kEUR 3,117 kEUR 9.1 %
Export ratio 81
%
77
%
5.2 %
EBITDA 390 kEUR 487 kEUR -20.1 %
EBITDA - Margin 9.3
%
12.1
%
-23.1 %
Depreciation -162 kEUR -184 kEUR -12.1 %
EBIT 228 kEUR 303 kEUR -24.9 %
Result of ordinary operation 366 kEUR 497 kEUR -26.5 %
Group period result (EAT) 358 kEUR 494 kEUR -27.5 %
Long term assets 5,202 kEUR 5,353 kEUR -2.8 %
Short term assets 12,681 kEUR 12,518 kEUR 1.3 %
Total Assets 17,883 kEUR 17,871 kEUR 0.1 %
Shareholders equity 16,493 kEUR 16,240 kEUR 1.6 %
Return on equity 4.3
%
6.1
%
-28.6 %
Equity ratio 92.2
%
90.9
%
1.4 %
Liquid funds and securities 8,393 kEUR 8,033 kEUR 4.5 %
Earnings per share according to
IFRS*
0.08 EUR 0.11 EUR -27.3 %
Earnings per Share according to
DVFA*
0.08 EUR 0.11 EUR -27.3 %
Number of employees at end of the
period
73 70 4.3 %
Total amount of issued share 4,500,000 4,500,000
* there of out standing 4,500,000 4,500,000

Consolidated profit and loss statement of 1 January 2006 to 30 June 2006

Apr.-June
2006
EUR
Apr.-June
2005
EUR
Change Jan.-June
2006
EUR
Jan.-June
2005
EUR
Change
Sales 2,031,827 1,968,352 3.2% 4,213,353 4,041,302 4.3%
Increase/decrease of finished goods and work in 80,960 -29 >100.0% 97,277 -43,018 >100.0%
progress
Other capitalized company work
23,425 0 100.0% 51,195 0 100.0%
Other operating income 43,934 65,920 -33.4% 81,560 157,714 -48.3%
2,180,146 2,034,243 7.2% 4,443,385 4,155,998 6.9%
Materials
Raw materials, supplies and
purchased goods -1,015,653 -842,693 20.5% -2,013,241 -1,815,169 10.9%
Expenses for services -49,004 -36,791 33.2% -94,087 -72,860 29.1%
-1,064,657 -879,484 21.1% -2,107,328 -1,888,029 11.6%
Gross profit 1,115,489 1,154,759 -3.4% 2,336,057 2,267,969 3.0%
Personnel costs
Wages and salaries -426,787 -362,280 17.8% -848,017 -799,198 6.1%
Social security and pension costs -95,574 -81,817 16.8% -191,211 -175,408 9.0%
-522,361 -444,097 17.6% -1,039,228 -974,606 6.6%
Depreciation on tangible and intangible assets -86,860 -92,180 -5.8% -161,705 -183,995 -12.1%
Other operating expenses -483,557 -412,620 17.2% -907,304 -805,838 12.6%
Operating result 22,711 205,862 -89.0% 227,820 303,530 -24.9%
Income from accured dividend 37,970 50,307 -24.5% 41,575 50,307 -17.4%
Other interest and similar income 30,541 29,903 2.1% 65,273 64,039 1.9%
Income from securities trading 45,738 74,451 -38.6% 74,238 92,493 -19.7%
Interest and other expenses -7,727 -3,231 >100.0% -8,205 -13,100 -37.4%
Loss from securities trading 0 0 0.0% -35,069 0 100.0%
Financial result 106,522 151,430 -29.7% 137,812 193,739 -28.9%
Result of ordinary operation 129,233 357,292 -63.8% 365,632 497,269 -26.5%
Income Taxes -16,768 -11,423 46.8% -34,003 -22,207 53.1%
Result of ordinary operation 112,465 345,869 -67.5% 331,629 475,062 -30.2%
Minority interests -15,592 2,484 >100.0% -26,665 -18,823 41.7%
Group period result 128,057 343,385 -62.7% 358,294 493,885 -27.5%
EBITDA 109,571 298,042 -63.2% 389,525 487,525 -20.1%
Result per share basic 0.03 0.08 -62.5% 0.08 0.11 -27.3%

Consolidated balance sheet 30 June 2006

Assets 30. June 2006
EUR
31. December 2005
EUR
Change
A. Long term assets
I. Intangible assets
1. Development costs 370,724 369,128 0.4%
2. Other intangible assets 18,360 22,769 -19.4%
3. Goodwill 75,750 75,750 0.0%
464,834 467,647 -0.6%
II. Tabgible assets
1. Property and plants 1,461,020 1,498,886 -2.5%
2. Technical facilities and machinery 234,954 258,098 -9.0%
3. Other equipment, factory and office equipment 97,158 77,453 25.4%
4. Payments in advance 14,222 6,110 >100.0%
1,807,354 1,840,547 -1.8%
III. Deferred taxes 2,929,432 2,963,435 -1.1%
5,201,620 5,271,629 -1.3%
B. Short term assets
I. Inventories
1. Raw materials 611,874 550,347 11.2%
2. Unfinished goods 714,820 591,459 20.9%
3. Finished goods 1,190,468 1,154,414 3.1%
2,517,162 2,296,220 9.6%
II. Receivables and other assets
1. Trade receivables 1,546,527 1,686,104 -8.3%
2. Tax receivables 185,834 80,287 >100.0%
3. Other assets 38,769 35,839 8.2%
1,771,130 1,802,230 -1.7%
III. Securities 5,080,108 3,218,121 57.9%
IV. Cash and cash equivalents 3,312,752 5,965,441 -44.5%
12,681,152 13,282,012 -4.5%
17,882,772 18,553,641 -3.6%
Liabilities
A. Equity
I. Subscribed capital 4,500,000 4,500,000 0.0%
II. capital reserves 7,570,000 7,570,000 0.0%
III. Other reserves 4,387,419 4,989,766 -12.1%
IV. Minority interest 35,851 62,522 -42.7%
16,493,270 17,122,288 -3.7%
B. Special reserve for investments 643,006 682,709 -5.8%
C. Short Term liabilities
1. Received payments 1,995 2,454 -18.7%
2. Trade accounts payable 201,955 198,921 1.5%
3. Tax liabilities 22,781 18,301 24.5%
4. Other Liabilities 519,765 528,968 -1.7%
746,496 748,644 -0.3%
17,882,772 18,553,641 -3.6%

7

Group cash flow statement of 01 January 2006 to 30 June 2006

Jan.-June 2006
kEUR
Jan.- June 2005
kEUR
Group period result 358 494
Earnings Minority interests -26 -19
Other costs affecting income/expenses 0 3
Dividend income -42 -50
Interest income -65 -64
Interest costs 8 13
Decrease of deferred taxes 34 22
Depreciation on tangible assets 162 184
Income from securities trading -74 -92
Loss from securities trading 35 0
Amortisation of subsidies and grant -40 -57
Brutto-Cashflow 350 434
Decrease / increase of inventories -221 -570
Decrease / increase of trade receivables 31 -189
Increase of short term liabilities -2 247
Incoming payments from dividends 42 50
Incoming payments from interest 65 64
Outgoing payments from interest -8 -13
Cashflow from operating activity 257 23
Payments for capital investments to fixed assets -126 -107
Incoming payment from financial assets 1,430 1,251
Outgoing payments from financial assets -2,773 -1,039
Cashflow from investing activities -1,469 105
Cash inflow from minority interest 0 0
Dividend payments -1,440 -1,260
Increase / decrease short term liabilities to bank 0 -660
Cashflow from financial activities -1,440 -1,920
Change in cash and cash equivalents -2,652 -1,792
Cash and cash equivalents at beginning of the reporting period 5,965 6,382
Cash and cash equivalents at the end of the reporting period 3,313 4,590

Group equity change calculation by 30.June 2006

Other reserves
Subscribed
capital
Capital
reserve
Market
evaluation
reserve
Currency
conversion
reserve
Result
achieved
in the
group
Minority
interests
Equity
EUR EUR EUR EUR EUR EUR EUR
1. January 2005 4,500,000 7,528,332 96,774 1,004 4,615,507 31,104 16,772,721
Not realized profit/
losses from evaluation
of securities
226,019 21,481 247,500
Currency conversion in
the Group
2,727 1,523 4,250
Dividend paid out to
shareholders
-1,260,000 -1,260,000
Group period result 493,885 -18,822 475,063
30. June 2005 4,500,000 7,528,332 322,793 3,731 3,870,873 13,805 16,239,534
1. January 2006 4,500,000 7,570,000 150,816 4,542 4,834,408 62,522 17,122,288
Not realized profit/
losses from evaluation
of securities
479,366 479,366
Currency conversion in
the Group
-7 -6 -13
Dividend paid out to
shareholders
-1,440,000 -1,440,000
Group period result 358,294 -26,665 331,629
30. June 2006 4,500,000 7,570,000 630,182 4,535 3,752,702 35,851 16,493,270

Segment reporting of 1 January 2006 to 30 June 2006

By Region Germany
Europe
USA
Others Total
Jan.-
June
2006
Jan.-
June
2005
Jan.-
June
2006
Jan.-
June
2005
Jan.-
June
2006
Jan.-
June
2005
Jan.-
June
2006
Jan.-
June
2005
Jan.-
June
2006
Jan.-
June
2005
kEUR kEUR kEUR kEUR kEUR kEUR kEUR kEUR kEUR kEUR
Sales 812 924 2,037 2,085 575 574 789 458 4,213 4,041
Gross Profit 507 585 1,096 1,126 309 310 424 247 2,336 2,268
Operating results 49 78 107 151 30 42 42 32 228 303
Including:
Depreciation of tangible and
fixed assets
35 48 76 91 21 25 30 20 162 184
Amortisation of grants and
subsidies and bonus
8 13 19 28 5 8 8 6 40 55
Asset cost for the period 122 106 0 0 0 0 4 1 126 107
Book values assets 2,263 2,394 0 0 0 0 9 1 2,272 2,395
According to areas of activity Analogue
Diagnostic Products
Digital
Diagnostic Products
Others Total
Jan.-June
2006
Jan.-June
2005
Jan.-June
2006
Jan.-June
2005
Jan.-June
2006
Jan.-June
2005
Jan.-June
2006
Jan.-June
2005
kEUR kEUR kEUR kEUR kEUR kEUR kEUR kEUR
Sales 1,840 1,956 1,729 1,546 644 539 4,213 4,041
Gross Profit 1,292 1,258 595 567 449 443 2,336 2,268
Operating result 257 229 121 172 -150 -98 228 303
Financial result 138 194
Taxes -34 -22
Minority share in result 26 19
Group period result 358 494
including:
Depreciation of tangible and fixed
assets
56 98 27 46 79 40 162 184
Amortisation of grants and subsidies
and bonus
17 27 16 21 7 7 40 55
Asset cost for the period 27 0 0 1 99 106 126 107
Book values assets 850 818 283 171 1,139 1,406 2,272 2,395
Deferred taxes 2,930 2,958 2,930 2,958
Short term assets 1,990 1,860 1,438 1,737 9,253 8,921 12,681 12,518
Total assets 2,840 2,678 1,721 1,908 13,322 13,285 17,883 17,871
Short term liabilities 88 110 83 88 575 779 746 977
Special reserve for received
investments
643 654 643 654

Explanation of the Interim Group Financial Statement for the period of 1 January 2006 – 30 June 2006

Balancing and evaluation methods

The Interim Group Financial Statement for the first half of 2006 was prepared according to the rules of the International Financial Reporting Standards (IFRS) valid on the accounting date and the interpretations of the International Financial Reporting Interpretations Committee (IFRIC), as they are compulsory in the European Union.

All balancing, evaluating and consolidation principles were maintained, as detailed in the Annex of the Group Financial Statement 2005.

Consolidated companies

There were no changes in the group of consolidated companies during the first half of 2006.

Explanations

Long-term assets

As per 30 June 2006, development cost for the self-developed intangible assets in the amount of kEUR 51 (previous year: kEUR 84) were capitalised. They relate to the development of the Stroke Risk Analyser SRA IV for the prevention of strokes.

There were further additions to the long-term assets in the amount of kEUR 75 (previous year: kEUR 23), which relate mainly to replacement investments in production plant as well as other furniture and fixtures.

Short-term assets

The short-term assets display greater changes mainly in the item of Securities and Cash. As per 30 June 2006, the securities holdings were increased through purchase by kEUR 2,773 (previous year: kEUR 1,039). There were disposals through sale in the amount of kEUR 1,430 (previous year: kEUR 1,251). Thus, a profit was realized in the amount of kEUR 74 (previous year: kEUR 92) and a loss was incurred in the amount of kEUR 35 (previous year: kEUR 0). The purchasing cost as per 30 June 2006 in the amount of kEUR 4,450 (previous year: kEUR 3,120) is matched by a stock evaluated on the basis of the prices of 30 June 2006 in the amount of kEUR 5,080 (previous year: kEUR 3,443). This results in profits not realised in the amount of kEUR 630 (previous year: kEUR 323). These are included in the item of Market Evaluation Provisions of the equity capital. The available cash was reduced by altogether kEUR 2,652 (previous year: kEUR 1,792). This is due mainly to the payment of the dividends on 13 June 2006 in the amount of kEUR 1,440 (previous year: kEUR 1,260) and the investment in the form of securities.

Equity capital

The subscribed capital of Geratherm Medical AG amounted to EUR 4,500,000 on 30 June 2006 and is split into 4,500,000 shares in the name of the bearer. The subscribed capital has been fully paid in. The company did not own any own shares on 30 June 2006.

The item of Market Evaluation Provisions, included for the first time in the business year of 2005, increased in the first half of 2006 by kEUR 479 (previous year: kEUR 226) to reach kEUR 630 (previous year: kEUR 323). Due to the stipulation by 31 December 2005 to conduct the adjustments of the previous year's figures, necessary due to the amendment of IAS 39, applying IAS 39.107, starting on 1 January 2004, we have adjusted the reference period of the first half of 2005. The adjustment relates to the restructuring in the amount of kEUR 21 from the item of Market Evaluation Provisions to Cumulated Profits.

Dates for further reporting

23/11/2006 Interim report 3rd Quarter of 2006
12/04/2007 Annual Report 2006
17/04/2007 Analyst Presentation / MedTech Day
23/05/2007 Interim Report 1st Quarter 2007
11/06/2007 Annual General Meeting
23/08/2007 Interim Report 2nd Quarter 2007
22/11/2007 Interim Report 3rd Quarter 2007

Talk to a Data Expert

Have a question? We'll get back to you promptly.